# BioNTech SE

BioNTech SE is an Asset Manager based in Mainz, Germany.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Mainz, Germany
- **Region:** Europe
- **Address:** Mainz, Germany
- **Founded:** 2008
- **Assets under management:** Undisclosed
- **Website:** biontech.de
- **LinkedIn:** https://www.linkedin.com/company/biontech-se

## Regulatory record

- **Reports private funds:** No

## About

BioNTech SE was founded in 2008 in Mainz, Germany, by husband-and-wife scientists Uğur Şahin and Özlem Türeci, who had spent years researching messenger RNA as a therapeutic delivery mechanism. The firm went public on the Nasdaq in 2019 and became a household name in 2020 when its BNT162b2 vaccine, developed in partnership with Pfizer, became the first mRNA vaccine authorized for emergency use. The company’s strategy revolves around its proprietary mRNA platform and deep pipeline of oncology candidates, covering solid tumors, hematological cancers, and infectious diseases. As of mid-2025, BioNTech has over 20 clinical-stage programs, including individualized neoantigen therapies and bispecific antibodies. It operates primarily in the United States and Europe, with additional development and manufacturing sites in Germany and the US, and has struck co-investment and licensing deals with partners such as Pfizer, Fosun Pharma, and Regeneron. By 2023, BioNTech had generated cumulative vaccine revenue exceeding $40 billion, much of which it reinvested into R&D and infrastructure. The firm employs roughly 6,000 people across its Mainz headquarters, a Cambridge, Massachusetts research hub, and multiple German sites. In July 2024, BioNTech announced a $250 million expansion of its personalized cancer vaccine manufacturing capacity in Germany. BioNTech’s structural differentiator is its dual identity as a publicly traded biotech company with a dominant commercial product and the scientific focus of a creator-led research firm. The Şahin-Türeci governance model retains long-term strategic control even as the company funds its pipeline with product revenue rather than equity dilution or debt.

## Sectors

- Biopharmaceuticals
- Immunotherapy
- mRNA Therapeutics

## Offices

- Cambridge, MA, United States
- Berlin, Germany

## People

- Prof. Uğur Şahin — CEO and Co-Founder
- Dr. Özlem Türeci — Chief Medical Officer and Co-Founder
- Jens Holstein — Chief Financial Officer

## Questions

### Who leads investment and strategic decisions at BioNTech?

BioNTech is led by co-founders Prof. Uğur Şahin (CEO) and Dr. Özlem Türeci (Chief Medical Officer), along with CFO Jens Holstein. The executive team sets scientific and capital-allocation priorities; the company does not operate a separate investment office or family office overlay.

### How does BioNTech deploy its capital?

BioNTech reinvests the majority of its operating revenue into R&D and manufacturing expansion. As of 2025, it had not established a dedicated investment arm or venture fund. Its capital deployment is primary internal — pipeline programs, clinical trials, and manufacturing scale-up — with occasional licensing and co-development deals with external biopharma partners.

### What investment stages does BioNTech focus on?

BioNTech does not make external financial investments. Its internal capital deployment targets clinical-stage drug development — primarily Phase 1 through Phase 3 trials — and early commercial manufacturing. The company does not disclose any venture or private equity allocation.

### Which sectors does BioNTech operate in?

BioNTech is a biopharmaceutical company specializing in mRNA-based therapeutics for cancer immunotherapy, infectious disease vaccines, and personalized medicine. It does not invest outside healthcare.

### How is BioNTech related to Pfizer or other partners?

BioNTech co-developed and co-commercialized the COVID-19 vaccine BNT162b2 with Pfizer, sharing gross profits equally. It has independent rights to its pipeline programs. Additional partners include Fosun Pharma (distribution rights in China) and Regeneron (for bispecific antibody programs).

## Related profiles

- [SB Management](https://altss.com/profile/sb-management)
- [TechTarget](https://altss.com/profile/techtarget)

---

Updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/biontech-se

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology